Intravenous busulfan decreases hepatic venoocclusive disease and overall 100-day mortality versus oral busulfan as part of conditioning regimen for autologous and allogeneic stem cell transplantation in children

被引：0
|
作者：
Molina, J. R.
Gonzalez, M.
Verdeguer, A.
Martinez, A.
Badell, I.
Diaz, M. A.
Maldonado, M.
Gonzalez, E.
Munoz, A.
Gomez, P.
机构：
来源：
BONE MARROW TRANSPLANTATION | 2008年 / 41卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S290 / S291
页数：2
相关论文
共 50 条
  • [31] Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150)
    Jung, Sung-Hoon
    Lee, Je-Jung
    Kim, Jin Seok
    Min, Chang-Ki
    Kim, Kihyun
    Choi, Yunsuk
    Eom, Hyeon-Seok
    Joo, Young Don
    Kim, Sung-Hyun
    Kwak, Jae-Yong
    Kang, Hye Jin
    Lee, Jae Hoon
    Lee, Ho Sup
    Mun, Yeung-Chul
    Moon, Joon Ho
    Sohn, Sang Kyun
    Park, Seong Kyu
    Park, Yong
    Shin, Ho-Jin
    Yoon, Sung-Soo
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (05) : 923 - 929
  • [32] Intravenous (IV) vs oral busulfan (BU) as part of a BU/CY (cyclophosphamide) preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT): Decreased incidence of hepatic veno-occlusive disease (VOD).
    Kashyap, A
    Wingard, J
    Cagnoni, P
    Tarantolo, S
    Fernandez, H
    Hu, W
    Gilfillan, K
    Faccuseh, M
    Niland, J
    Vaughan, W
    Jones, R
    Blume, K
    Champlin, R
    Forman, SJ
    Andersson, BS
    BLOOD, 1999, 94 (10) : 321B - 321B
  • [33] COST EFFECTIVENESS ANALYSIS OF BUSULFAN plus CYCLOPHOSPHAMIDE (BUCY2) AS CONDITIONING REGIMEN BEFORE ALLOGENEIC HUMAN STEAM CELL TRANSPLANTATION (HSCT): COMPARISON OF ORAL VERSUS IV BUSULFAN
    Tellez Giron, G.
    Salgado, J. L.
    Soto, H.
    VALUE IN HEALTH, 2012, 15 (04) : A220 - A220
  • [34] Clinical results of allogeneic haematopoietic stem cell transplantation following a new intravenous busulfan dosing strategy as part of BuCy conditioning regimen in children and adolescents:: sustained engraftment and less toxic deaths
    Esperou, H.
    Vassal, G.
    Neven, B.
    Mechinaud, F.
    Galambrun, C.
    Yakouben, K.
    Paillard, C.
    Bordigoni, P.
    Levrault, C.
    Zouabi, H.
    Michel, G.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S200 - S200
  • [35] Oral versus Intravenous Fludarabine as Part of a Reduced-Intensity Conditioning for Allogeneic Stem Cell Transplantation
    Velazquez-Sanchez-de-Cima, Sara
    Zamora-Ortiz, Gabriela
    Hernandez-Reyes, Jesus
    Daniel Rosales-Duron, Alan
    Patricia Gonzalez-Ramirez, Monica
    Angela Martagon-Herrera, Nora
    Ruiz-Delgado, Guillermo J.
    Ruiz-Argueelles, Guillermo J.
    ACTA HAEMATOLOGICA, 2014, 132 (01) : 125 - 128
  • [36] Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation
    Bartelink, Imke H.
    Bredius, Robbert G. M.
    Ververs, Tessa T.
    Raphael, Martine F.
    van Kesteren, Charlotte
    Bierings, Marc
    Rademaker, Carin M. A.
    den Hartigh, J.
    Uiterwaal, Cuno S. P. M.
    Zwaveling, Juliette
    Boelens, Jaap J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (01) : 88 - 98
  • [37] Final clinical results of a new intravenous busulfan dosing strategy as part of bucy conditioning regimen in children and adolescents undergoing allogeneic hematopoietic stem cell transplantation (HSCT): Low mortality and long term disease free survival in myeloid leukemias
    Esprou, H.
    Vassal, G.
    Neven, B.
    Mechinaud, F.
    Bertrand, Y.
    Galambrun, C.
    Yakouben, K.
    Paillard, C.
    Bordigoni, P.
    Levrault, C.
    Zouabi, H.
    Michel, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 370 - 371
  • [38] Intravenous Busulfan dosed once daily or four times daily as part of the standard BuCy preparative regimen for allogeneic stem cell transplantation.
    Shaughnessy, PJ
    Bachier, C
    Alexander, L
    LeMaistre, CF
    BLOOD, 2005, 106 (11) : 417B - 417B
  • [39] Autologous haematopoietic stem cell transplantation after myeloablative regimen with oral or intravenous busulfan in acute myeloid leukaemia - a single-centre experience
    Cioch, M.
    Jawniak, D.
    Kotwica, K.
    Wach, M.
    Manko, J.
    Walter-Croneck, A.
    Legiec, W.
    Dmoszynska, A.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S91 - S92
  • [40] Toxicity and early response after single daily dose of intravenous busulfan and melphalan as conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma
    de la Rubia, J.
    Lahuerta, J. J.
    Gonzalez, J. D.
    Ribas, P.
    Solano, C.
    Sanz, M. A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 192 - 192
12345